StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report released on Friday morning. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital assumed coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $2.94 on Friday. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42. The stock has a market cap of $76.68 million, a P/E ratio of -3.92 and a beta of 1.00. The firm has a fifty day moving average price of $2.79 and a 200 day moving average price of $2.73.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. Sell-side analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NSPR. Parkman Healthcare Partners LLC acquired a new position in InspireMD during the 3rd quarter worth approximately $279,000. Essex Investment Management Co. LLC acquired a new position in InspireMD during the fourth quarter worth $191,000. Northern Trust Corp raised its position in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after acquiring an additional 24,452 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after acquiring an additional 18,233 shares during the period. Finally, Legato Capital Management LLC purchased a new stake in shares of InspireMD during the 4th quarter worth $47,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.